EMA Withdrawn: Nyxthracis (previously Obiltoxaximab SFL) (nyxthracis) — SFL Pharmaceuticals Deutschland GmbH

View source ↗

Summary

EMA has withdrawn Nyxthracis (formerly Obiltoxaximab SFL) from the market for anthrax.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthrax

Drugs mentioned

• Nyxthracis (obiltoxaximab)

Snippet

Status: Withdrawn. Therapeutic area: Anthrax. MAH: SFL Pharmaceuticals Deutschland GmbH. Decision date: 14/12/2022